IGC Pharma updates investor presentation: Phase 2 CALMA trial >80% enrolled, interim data show agitation reduction

IGC Pharma, Inc.

Phase 2 CALMA trial for IGC-AD1 in agitation in Alzheimer's: >80% of 146 target participants completed dosing.
Blinded pooled data (n=107) show LS mean CMAI change of -13.6 at week 2 and -14.9 at week 6 from baseline.
Interim analysis (n=26) showed IGC-AD1 numerically earlier and larger CMAI reduction vs published brexpiprazole data.
Sleep disturbance reduced 71% at week 2 (p=0.012) and 78% at EOT (p=0.02) in interim analysis.
Current market cap ~$30M; presentation outlines potential valuation inflection to $350M-$750M post positive Phase 2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.